Home » KineMed and Merck Enter Collaboration in Atherosclerosis
KineMed and Merck Enter Collaboration in Atherosclerosis
KineMed, Inc., a pathway-based drug discovery and development company, announced today a non-exclusive collaboration with Merck & Co., Inc., under which KineMed's proprietary reverse cholesterol transport (RCT) technology will be used to evaluate investigational compounds discovered by Merck.
PR Newswire
Upcoming Events
-
07May
-
14May
-
30May